Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection.
Liver toxicity is a common side effect of antiretroviral therapy, particularly in subjects coinfected with the hepatitis C virus (HCV). The incidence of severe liver toxicity after initiation of treatment with lopinavir (LPV) as well as its possible association with LPV plasma levels were assessed in 120 HIV-infected patients (52% coinfected by HCV). The incidence of severe liver toxicity at 3 months was 1.7% and the cumulative incidence at 12 months was 4%. The development of severe liver toxicity was associated with HCV coinfection but not with LPV plasma levels.
Service of Infectious Diseases and Pharmacy Unit, Hospital Carlos III, 28035 Madrid, Spain.
Daniel
D
González-Requena
Marina
M
Núñez
Inmaculada
I
Jiménez-Nacher
Juan
J
González-Lahoz
Vincent
V
Soriano
D000328:Adult; D019380:Anti-HIV Agents / Q000633:toxicity*; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006526:Hepatitis C / Q000150:complications* / Q000473:pathology; D006801:Humans; D015994:Incidence; D008099:Liver / Q000187:drug effects / Q000473:pathology* / Q000821:virology; D061466:Lopinavir; D008297:Male; D011744:Pyrimidinones / Q000633:toxicity*
D019380:Anti-HIV Agents; D011744:Pyrimidinones; D061466:Lopinavir